Preclinical biotechs taking larger chunk of venture funding

Preclinical biotechs are increasingly taking in more venture than their clinical counterparts, including later-stage rounds such as series C, according to an analysis of financings in BioCentury’s BCIQ database.

In 2018, the 196 venture rounds raised by preclinical biotechs accounted for 58% of all biotech venture financings. Last year, that fraction rose to 66%, with 269 financings raised by preclinical companies...